Positive Outcome After Intentional Overdose of Dabigatran
- First Online:
Dabigatran (Pradaxa™), an orally active direct thrombin inhibitor, was approved by the United States Food and Drug Administration for the prevention of stroke in patients with atrial fibrillation in October 2010. Life-threatening consequences from dabigatran therapy include hemorrhage and bleeding complications, but they typically occur after renal impairment. We describe the first case report of intentional, acute overdose with dabigatran.
A 57-year-old woman with a medical history of depression and atrial fibrillation presented to the emergency department after ingesting 11.25 g of dabigatran in a suicide attempt. Despite an ecchymosis indicative of prior trauma, there was no evidence of acute bleeding. After receiving gastric lavage and activated charcoal therapy in the emergency department, she was admitted to the ICU. On presentation, dabigatran blood levels measured 970 ng/mL and thrombin clot times measured above the testable limits (>120 s) until 52 h post-arrival. The remainder of her clinical course was uncomplicated, and the patient was transferred to an inpatient psychiatric unit for depression follow-up.
This case shows the clinical course of a patient with an acute, massive dabigatran overdose with no significant clinical consequences. Currently, there is no ideal method to monitor anticoagulation levels; there is no pharmacologic reversal method, and hemodialysis is an undesirable treatment option.
KeywordsPradaxa Toxicity Anticoagulation Bleed Hemorrhage
- 1.US-FDA. (2010) FDA approves Pradaxa to prevent stroke in people with atrial fibrillation. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm230241.htm. Accessed 17 July 2012
- 2.US-FDA. (2011) FDA drug safety communication: safety review of post-market reports of serious bleeding events with the anticoagulant Pradaxa (dabigatran etexilate mesylate). http://www.fda.gov/drugs/drugsafety/ucm282724.htm. Accessed 5 May 2012
- 7.Fellows SE et al (2012) Hemorrhagic gastritis with dabigatran in a patient with renal insufficiency. J Emerg Med. doi:10.1016/j.jemermed.2012.02.042
- 13.US-FDA. (2012) FDA advisory committee briefing document—dabigatran etexilate (DE). http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/cardiovascularandrenaldrugsadvisorycommittee/ucm226009.pdf. Accessed 20 May 2012
- 16.Van Ryn J, Sieger P, Kink-Eiband M, Gansser D, Clemens A. (2009) Adsorption of dabigatran etexilate in water or dabigatran in pooled human plasma by activated charcoal in vitro. In: 51st ASH Annual Meeting and Exposition, Ernest N. Morial Convention Center, New Orleans, 5-8 Dec 2009. https://ash.confex.com/ash/2009/webprogram/Paper21383.html. Accessed 15 May 2012